Trial Profile
A phase IV trial assessing the safety of icotinib in patients with advanced non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Nov 2015
Price :
$35
*
At a glance
- Drugs Icotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 24 Nov 2015 New trial record